ALK

01.12.2021 – 10:01
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
Copenhagen, Denmark (ots/PRNewswire) - - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have been published in The Lancet Regional Health - Europe - REACT demonstrated the real-world effectiveness of allergy immunotherapy (AIT) - including ALK products - in allergic ...
mehr
03.06.2019 – 13:15
Targeted Early Treatment With ALK's ACARIZAX® Could Improve Allergic Asthma Treatment, Allergy Congress Hears
- Easy to measure biomarkers could identify a group of patients who benefit even more from ACARIZAX® treatment of house dust mite (HDM)-induced allergic asthma - Early identification of patients would allow earlier treatment intervention - With its HDM SLIT-tablet, ALK is well-placed to lead the way on ...
mehr
07.07.2017 – 11:01
ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehr
30.06.2017 – 12:20
ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehr
20.06.2017 – 11:02
ALK Symposium Reveals Early Treatment is Critical for Respiratory Allergic Disease in Children and Adolescents
Hørsholm, Denmark (ots/PRNewswire) - - Allergic rhinitis has a major impact on children's quality of life - Children with allergic rhinitis have an increased risk of developing asthma - Early treatment may prevent asthma symptoms In a symposium sponsored by ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), leading ...
mehr
27.02.2017 – 14:49
ALK's ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended as a Treatment Option in Patients With House Dust Mite Allergic Asthma
Hørsholm, Denmark (ots/PRNewswire) - ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a ...
mehr
09.06.2014 – 15:02
ALK Presents Phase III Data on House Dust Mite SLIT-tablet at EAACI Annual Congress in Copenhagen
Hørsholm, Denmark (ots/PRNewswire) - First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European regulatory filing in 2H 2014 Today, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has presented key trial results on its new sublingual allergy ...
mehr
08.06.2014 – 19:01
Allergy Experts Address Pivotal Questions in Treatment of Grass Pollen Allergy Sufferers
Copenhagen, Denmark (ots/PRNewswire) - And highlight a decade of clinical evidence demonstrating long-term efficacy and tolerability of once-daily GRAZAX(R) SLIT-tablet at EAACI 2014 A group of eminent allergy and respiratory professors presented data specifically addressing numerous key questions within the allergy community concerning grass SLIT-tablets, with ...
mehr